Severe type of Erythema Multiforme (EM major) due to Administration of Anti-PD-1 Antibody Drug

Shoya Yano, Aika Okuno, Fukumi Furukawa

Article ID: 1247
Vol 5, Issue 1, 2021

VIEWS - 1644 (Abstract) 412 (PDF)

Abstract


Immune checkpoint inhibitors can sometimes cause unexpected skin side effects. Special attention should be paid to a severe form of erythema multiforme (EM), toxic epidermal necrolysis and Stevens-Johnson syndrome. We experienced a patient who took 10 weeks from drug discontinuation to the onset of EM major.


Keywords


Immune Checkpoint Inhibitors; Immune-related Adverse Events; Erythema Multiforme; Erythema Multiforme Major

Full Text:

PDF


References


1. Furukawa F. The Nobel Prize in Physiology or Medicine 2018 was awarded to cancer therapy by inhibition of negative immune regulation. Trends Immunother 2018; 2. doi: 10.24294/ti.v2.i3.1065

2. Furukawa F. Immune checkpoint inhibitors and irAEs. Trends Immunother 2018; 2. doi:10.24294/ti.v2.i2.930

3. Seidel JA, Otsuka A, Kabashima K. Treating tumors with immune checkpoint inhibitors: Rationale and limitations. Trends Immunother 2017; 1(1): 2–9. doi:10.24294/ti.v1.i1.20

4. Inaba H, Ariyasu H, Okuhira H, et al. Endocrine dysfunctions during treatment of immune-check point inhibitors. Trends Immunother 2018; 2. doi: 10.24294/ti.v2.i2.606.

5. Durrechou Q, Domblides C, Sionneau B, et al. Management of immune checkpoint inhibitor toxicities. Cancer Management and Research 2020; 12: 9139–9158. doi: 10.2147/CMAR.S218756

6. Garrett NFMDS, da Costa ACC, Damiani G, et al. Patients with lung cancer undergoing immune checkpoint inhibitors: A meta-analysis of dermato-logical toxicities. Critical Reviews in Oncolo-gy/Hematology 2020; 152. doi: 10.1016/j.critrevonc.2020.102983

7. Adachi E, Yokoyama E, Yamagami Y, et al. Bullous pemphigoid induced by nivolumab in a patient with malignant melanoma. Trends Immunother 2020; 4(1): 15–17. doi:10.24294/ti.v4.i1.1210

8. Hirata K, Shimizu T, Oguri T, et al. A case of toxic epidermal necrolysis following treatment with pembrolizumab. Japanese Journal of Clinical Der-matology 2020; 74: 311–316. doi:10.11477/mf.1412205986

9. Osa A, Uenami T, Koyama S, et al. Clinical impli-cations of monitoring nivolumab immunokinetics in non–small cell lung cancer patients. JCI Insight 2018; 3(19): 1–16. doi:10.1172/jci.insight.59125

10. Michot JM, Bigenwald C, Champiat S, et al. Im-mune-related adverse events with immune check-point blockade: a comprehensive review. European Journal of Cancer 2016; 54: 139–148. doi: 10.1016/j.ejca.2015.11.016

11. Morino I, Okuno A, Hirakawa Y, et al. Epidermal growth factor inhibitor-induced cutaneous toxicity improves with moisturizers. Trend Immunother 2020; 4(2): 81–86. doi:10.24294/ti.v4.i1.1187




DOI: https://doi.org/10.24294/ti.v5.i1.1247

Refbacks

  • There are currently no refbacks.


Copyright (c) 2021 Shoya Yano

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

This site is licensed under a Creative Commons Attribution 4.0 International License.